{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:36:27Z","timestamp":1791765387667,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s11886-024-02065-y","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T08:01:49Z","timestamp":1714636909000},"page":"651-659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Medical Therapy for Peripheral Artery Disease"],"prefix":"10.1007","volume":"26","author":[{"given":"Mario Enrico","family":"Canonico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie N.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Kevin","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"2065_CR1","doi-asserted-by":"crossref","unstructured":"\u2022 Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, et al. Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. Circulation. 2021;144(9).\u00a0The paper provides updates on the epidemiology and current knowledge in PAD.","DOI":"10.1161\/CIR.0000000000001019"},{"key":"2065_CR2","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA\/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(12).\u00a0The paper is the latest AHA\/ACC LEPAD guidelines.","DOI":"10.1161\/CIR.0000000000000501"},{"issue":"9","key":"2065_CR3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"\u2022\u2022 Aboyans V, Ricco JB, Bartelink MLEL, Bj\u00f6rck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763\u2013816. The paper is the latest ESC PAD guidelines.","journal-title":"Eur Heart J"},{"issue":"7","key":"2065_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/CIRCULATIONAHA.119.039773","volume":"140","author":"CN Hess","year":"2019","unstructured":"Hess CN, Huang Z, Patel MR, Baumgartner I, Berger JS, Blomster JI, et al. Acute Limb Ischemia in Peripheral Artery Disease. Circulation. 2019;140(7):556\u201365.","journal-title":"Circulation"},{"key":"2065_CR5","doi-asserted-by":"crossref","unstructured":"Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, et al. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. JAMA Cardiol. 2020.","DOI":"10.1001\/jamacardio.2020.4390"},{"issue":"6","key":"2065_CR6","first-page":"100513","volume":"1","author":"RW King","year":"2022","unstructured":"King RW, Canonico ME, Bonaca MP, Hess CN. Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. J Soc Cardiovasc Angiogr Interv. 2022;1(6):100513.","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"issue":"6","key":"2065_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/1358863X18775594","volume":"23","author":"JS Berger","year":"2018","unstructured":"Berger JS, Abramson BL, Lopes RD, Heizer G, Rockhold FW, Baumgartner I, et al. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vasc Med. 2018;23(6):523\u201330.","journal-title":"Vasc Med"},{"issue":"4","key":"2065_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"\u2022\u2022 Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. Circulation. 2018;137(4):338\u201350. The paper is a subgroup analysis from FOURIER demonstrating the efficacy of evolocumab in PAD patients.","journal-title":"Circulation"},{"issue":"18","key":"2065_CR9","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.jacc.2018.08.002","volume":"72","author":"N Narula","year":"2018","unstructured":"\u2022 Narula N, Dannenberg AJ, Olin JW, Bhatt DL, Johnson KW, Nadkarni G, et al. Pathology of Peripheral Artery Disease in Patients With Critical Limb Ischemia. J Am Coll Cardiol. 2018;72(18):2152\u201363. The paper highlights the pathophysiology of ALI including the role of thrombo-embolism.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2065_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1001\/jamacardio.2021.3987","volume":"7","author":"MA Creager","year":"2022","unstructured":"Creager MA, Hamburg NM. Smoking Cessation Improves Outcomes in Patients With Peripheral Artery Disease. JAMA Cardiol. 2022;7(1):15.","journal-title":"JAMA Cardiol"},{"key":"2065_CR11","doi-asserted-by":"crossref","unstructured":"Ebbert J, Burke MV, Hays JT. Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence. Patient Prefer Adherence. 2016;435.","DOI":"10.2147\/PPA.S83469"},{"key":"2065_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.atherosclerosis.2018.05.049","volume":"275","author":"N L\u00f3pez-Laguna","year":"2018","unstructured":"L\u00f3pez-Laguna N, Mart\u00ednez-Gonz\u00e1lez MA, Toledo E, Babio N, Sorl\u00ed JV, Ros E, et al. Risk of peripheral artery disease according to a healthy lifestyle score: The PREDIMED study. Atherosclerosis. 2018;275:133\u201340.","journal-title":"Atherosclerosis"},{"key":"2065_CR13","doi-asserted-by":"crossref","unstructured":"Treat-Jacobson D, McDermott MM, Beckman JA, Burt MA, Creager MA, Ehrman JK, et al. Implementation of Supervised Exercise Therapy for Patients With Symptomatic Peripheral Artery Disease: A Science Advisory From the American Heart Association. Circulation. 2019;140(13).","DOI":"10.1161\/CIR.0000000000000727"},{"issue":"18","key":"2065_CR14","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1001\/jama.2015.14851","volume":"314","author":"F Fakhry","year":"2015","unstructured":"Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JAW, Hoffmann WH, et al. Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication. JAMA. 2015;314(18):1936.","journal-title":"JAMA"},{"key":"2065_CR15","doi-asserted-by":"publisher","first-page":"a1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J Belch","year":"2008","unstructured":"Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840\u2013a1840.","journal-title":"BMJ"},{"issue":"9","key":"2065_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jama.2010.221","volume":"303","author":"FGR Fowkes","year":"2010","unstructured":"Fowkes FGR, Price JF, Stewart MCW, Butcher I, Leng GC, Pell ACH, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841\u20138.","journal-title":"JAMA"},{"issue":"39","key":"2065_CR17","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1093\/eurheartj\/ehab390","volume":"42","author":"V Aboyans","year":"2021","unstructured":"\u2022\u2022 Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021;42(39):4013\u201324. The paper is the latest ESC consensus on antithrombotic therapy in PAD, including last evidence after LER.","journal-title":"Eur Heart J"},{"issue":"9038","key":"2065_CR18","first-page":"1329","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee Lancet. 1996;348(9038):1329\u201339.","journal-title":"CAPRIE Steering Committee Lancet"},{"issue":"4","key":"2065_CR19","first-page":"164","volume":"10","author":"ME Canonico","year":"2023","unstructured":"Canonico ME, Piccolo R, Avvedimento M, Leone A, Esposito S, Franzone A, et al. Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. J Cardiovasc Dev Dis. 2023;10(4):164.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"2","key":"2065_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","volume":"30","author":"PP Cacoub","year":"2008","unstructured":"Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2008;30(2):192\u2013201.","journal-title":"Eur Heart J"},{"issue":"23","key":"2065_CR21","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","volume":"67","author":"MP Bonaca","year":"2016","unstructured":"Bonaca MP, Bhatt DL, Storey RF, Steg PhG, Cohen M, Kuder J, et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016;67(23):2719\u201328.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"2065_CR22","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","volume":"381","author":"PG Steg","year":"2019","unstructured":"Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309\u201320.","journal-title":"N Engl J Med"},{"key":"2065_CR23","unstructured":"Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, et al. Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. N Eng J Med. 2007;357(3):217\u201327."},{"issue":"14","key":"2065_CR24","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","volume":"127","author":"MP Bonaca","year":"2013","unstructured":"Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, et al. Vorapaxar in Patients With Peripheral Artery Disease. Circulation. 2013;127(14):1522\u20139.","journal-title":"Circulation"},{"issue":"4","key":"2065_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","volume":"52","author":"JJF Belch","year":"2010","unstructured":"Belch JJF, Dormandy J. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825-833.e2.","journal-title":"J Vasc Surg"},{"issue":"9","key":"2065_CR26","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","volume":"22","author":"G Tepe","year":"2012","unstructured":"Tepe G, Bantleon R, Brechtel K, Schmehl J, Zeller T, Claussen CD, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy\u2014the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol. 2012;22(9):1998\u20132006.","journal-title":"Eur Radiol"},{"key":"2065_CR27","doi-asserted-by":"crossref","unstructured":"Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. The Lancet. 2000;355(9201):346\u201351.","DOI":"10.1016\/S0140-6736(99)07199-8"},{"issue":"2","key":"2065_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1526602818760488","volume":"25","author":"F Moll","year":"2018","unstructured":"Moll F, Baumgartner I, Jaff M, Nwachuku C, Tangelder M, Ansel G, et al. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. J Endovasc Ther. 2018;25(2):158\u201368.","journal-title":"J Endovasc Ther"},{"issue":"21","key":"2065_CR29","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"\u2022\u2022 Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020;382(21):1994\u20132004. The VOYAGER-PAD trial demonstrated the efficacy of DPI in symptomatic LEPAD patients undergoing LER.","journal-title":"N Engl J Med"},{"issue":"23","key":"2065_CR30","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1161\/CIRCULATIONAHA.120.050465","volume":"142","author":"WR Hiatt","year":"2020","unstructured":"Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS, et al. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. Circulation. 2020;142(23):2219\u201330.","journal-title":"Circulation"},{"issue":"4","key":"2065_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2021.05.003","volume":"78","author":"RM Bauersachs","year":"2021","unstructured":"Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, et al. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. J Am Coll Cardiol. 2021;78(4):317\u201326.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2065_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ehj.2003.10.033","volume":"25","author":"J \u00d6stergren","year":"2004","unstructured":"\u00d6stergren J. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25(1):17\u201324.","journal-title":"Eur Heart J"},{"issue":"15","key":"2065_CR33","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"R Telmisartan","year":"2008","unstructured":"Telmisartan R. or Both in Patients at High Risk for Vascular Events. N Engl J Med. 2008;358(15):1547\u201359.","journal-title":"N Engl J Med"},{"issue":"1","key":"2065_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.109.142240","volume":"55","author":"AA Bavry","year":"2010","unstructured":"Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-DeHoff RM, Handberg EM, et al. Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease. Hypertension. 2010;55(1):48\u201353.","journal-title":"Hypertension"},{"issue":"1","key":"2065_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"\u2022\u2022 Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. The paper is the latest ESC guidelines on dyslipidemia including LDL-C target in ASCVD patients.","journal-title":"Eur Heart J"},{"key":"2065_CR36","doi-asserted-by":"crossref","unstructured":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20\u2008536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360(9326):7\u201322.","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"2065_CR37","doi-asserted-by":"crossref","unstructured":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645\u2013654.e1.","DOI":"10.1016\/j.jvs.2006.12.054"},{"issue":"41","key":"2065_CR38","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1093\/eurheartj\/ehu080","volume":"35","author":"DJ Kumbhani","year":"2014","unstructured":"Kumbhani DJ, Steg PhG, Cannon CP, Eagle KA, Smith SC, Goto S, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35(41):2864\u201372.","journal-title":"Eur Heart J"},{"issue":"25","key":"2065_CR39","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"12","key":"2065_CR40","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","volume":"6","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6(12):934\u201343.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"2065_CR41","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. J Am Coll Cardiol. 2022;80(14):1366\u2013418.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2065_CR42","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","volume":"74","author":"JW Jukema","year":"2019","unstructured":"\u2022\u2022 Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, et al. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. J Am Coll Cardiol. 2019;74(9):1167\u201376. The paper is a subgroup analysis from ODYSSEY OUTCOMES demonstrating the efficacy of alirocumab in PAD patients.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2065_CR43","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"1","key":"2065_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322.","journal-title":"N Engl J Med"},{"key":"2065_CR45","doi-asserted-by":"crossref","unstructured":"Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med. 2011;365(24):2255\u201367.","DOI":"10.1056\/NEJMoa1107579"},{"issue":"39","key":"2065_CR46","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"\u2022\u2022 Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140. The paper is the latest ESC guidelines on CVD management in DM patients including the role of SGLT2i and GLP-1RA in ASCVD patients.","journal-title":"Eur Heart J"},{"issue":"15","key":"2065_CR47","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"key":"2065_CR48","doi-asserted-by":"crossref","unstructured":"Badjatiya A, Merrill P, Buse JB, Goodman SG, Katona B, Iqbal N, et al. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. Circ Cardiovasc Interv. 2019;12(12).","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018"},{"issue":"7","key":"2065_CR49","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/dom.14700","volume":"24","author":"S Verma","year":"2022","unstructured":"Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, et al. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022;24(7):1288\u201399.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2065_CR50","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2337\/dc18-1094","volume":"41","author":"K Dhatariya","year":"2018","unstructured":"Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, et al. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care. 2018;41(10):2229\u201335.","journal-title":"Diabetes Care"},{"key":"2065_CR51","doi-asserted-by":"crossref","unstructured":"\u2022 Sillesen H, Debus ES, Enggaard RBB, Frenkel O, Heled Y, Mansor-Lefebvre S, et al. Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease: rationale and design of the STRIDE trial. Eur Heart J. 2021;42(Supplement_1).\u00a0This paper describes the design of the STRIDE trial investigating the role of GLP-1RA in PAD patients.","DOI":"10.1093\/eurheartj\/ehab724.2027"},{"issue":"4","key":"2065_CR52","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","volume":"137","author":"S Verma","year":"2018","unstructured":"Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, et al. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. Circulation. 2018;137(4):405\u20137.","journal-title":"Circulation"},{"issue":"12","key":"2065_CR53","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1161\/CIRCRESAHA.121.318258","volume":"128","author":"MP Bonaca","year":"2021","unstructured":"Bonaca MP, Hamburg NM, Creager MA. Contemporary Medical Management of Peripheral Artery Disease. Circ Res. 2021;128(12):1868\u201384.","journal-title":"Circ Res"},{"issue":"6","key":"2065_CR54","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/dom.14671","volume":"24","author":"JY Barraclough","year":"2022","unstructured":"Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL, Neuen BL, et al. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS<\/scp> Program and <scp>CREDENCE<\/scp> trial. Diabetes Obes Metab. 2022;24(6):1072\u201383.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2065_CR55","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","volume":"142","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, et al. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation. 2020;142(8):734\u201347.","journal-title":"Circulation"},{"issue":"7","key":"2065_CR56","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0002-9343(00)00569-6","volume":"109","author":"DL Dawson","year":"2000","unstructured":"Dawson DL, Cutler BS, Hiatt WR, Hobson RW, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109(7):523\u201330.","journal-title":"Am J Med"},{"issue":"5","key":"2065_CR57","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1161\/CIRCRESAHA.119.315600","volume":"126","author":"MM McDermott","year":"2020","unstructured":"McDermott MM, Criqui MH, Domanchuk K, Ferrucci L, Guralnik JM, Kibbe MR, et al. Cocoa to Improve Walking Performance in Older People With Peripheral Artery Disease. Circ Res. 2020;126(5):589\u201399.","journal-title":"Circ Res"},{"key":"2065_CR58","doi-asserted-by":"crossref","unstructured":"Canonico ME, Hsia J, Hess CN, Bonaca MP. Sex differences in guideline-directed medical therapy in 2021\u201322 among patients with peripheral artery disease. Vasc Med. 2023;1358863X2311553.","DOI":"10.1177\/1358863X231155308"},{"issue":"24","key":"2065_CR59","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1016\/j.jacc.2021.04.060","volume":"77","author":"CN Hess","year":"2021","unstructured":"Hess CN, Cannon CP, Beckman JA, Goodney PP, Patel MR, Hiatt WR, et al. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2021;77(24):3016\u201327.","journal-title":"J Am Coll Cardiol"},{"key":"2065_CR60","doi-asserted-by":"crossref","unstructured":"Sonderman M, Aday AW, Farber-Eger E, Mai Q, Freiberg MS, Liebovitz DM, et al. Identifying Patients With Peripheral Artery Disease Using the Electronic Health Record. JACC: Advances. 2023;2(7):100566.","DOI":"10.1016\/j.jacadv.2023.100566"},{"issue":"8","key":"2065_CR61","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/S0735-1097(23)02549-4","volume":"81","author":"CN Hess","year":"2023","unstructured":"\u2022 Hess CN, Nehler M, Daffron A, Morrison J, Buchanan C, Saseen JJ, et al. PRAGMATIC IMPLEMENTATION SCIENCE TO ASSESS LIPID OPTIMIZATION IN PERIPHERAL ARTERY DISEASE: PRIMARY RESULTS OF THE OPTIMIZE PAD-1 TRIAL. J Am Coll Cardiol. 2023;81(8):2105. This abstract includes the preliminary results of the OPTIMIZE PAD-1 trial, an implementation science study of lipid management in PAD patients.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02065-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-024-02065-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02065-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T07:17:53Z","timestamp":1719299873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-024-02065-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2065"],"URL":"https:\/\/doi.org\/10.1007\/s11886-024-02065-y","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"18 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Drs Canonico, Hess, Rogers, Bonaca receive salary support from CPC, a non-profit academic research organization affiliated with the University of Colorado, that receives or has received research grant\/consulting funding between July 2021 and July 2023 from the following organizations: Abbot Laboratories, Agios Pharmaceuticals, Inc., Alexion Pharma Godo Kaisha, Amgen Inc., Anthos Therapeutics, Inc., ARCA biopharma, Inc., AstraZeneca Pharma India, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd, AstraZeneca, Produtos Farmaceuticos, Lda, Atentiv, LLC, Bayer, Bayer (Proprietary) Limited, Bayer Aktiengesellschaft, Bayer Pharma AG, Beth Israel Deaconess Medical Center, Better Therapeutics, Boston Clinical Research Institute, LLC, Bristol-Myers Squibb, CellResearch Corporation Pte Ltd, Cleerly, Inc., Colorado Dept of Public Health and Environment, Cook Regentec LLC, CSL Behring LLC, Eidos Therapeutics, Inc., EPG Communication Holdings Ltd., Esperion Therapeutics, Inc, Faraday Pharmaceuticals, Inc., HeartFlow Inc, Insmed, Ionis Pharmaceuticals, IQVIA Inc., Janssen Pharmaceuticals, Inc, Janssen Research & Development, LLC, Janssen Scientific Affairs LLC, Lexicon Pharmaceuticals, Inc., LSG Corporation, MedImmune Limited, Medpace, Inc., Medscape, Merck Sharp & Dohme Corp., Nectero Medical Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk, Osiris Therapeutics, Inc., Pfizer, PPD Development, L.P., Prothena Biosciences Limited, Regeneron, Regents of the University of Colorado (aka UCD), Sanifit Therapeutics S.A., Sanofi, Silence Therapeutics PLC, Stanford University, Stealth BioTherapeutics Inc., The Brigham & Women's Hospital, Inc., Thrombosis Research Institute, University of Colorado Denver, University of Pittsburgh, VarmX, WraSer, LLC. Dr. Bonaca receives support from the AHA SFRN under award numbers 18SFRN3390085 (BWH-DH SFRN Center) and 18SFRN33960262 (BWH-DH Clinical Project). Dr. Bonaca also reports stock in Medtronic and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Drs Canonico, Hess, Rogers, Bonaca receive salary support from CPC, a non-profit academic research organization affiliated with the University of Colorado, that receives or has received research grant\/consulting funding between July 2021 and July 2023 from the following organizations: Abbot Laboratories, Agios Pharmaceuticals, Inc., Alexion Pharma Godo Kaisha, Amgen Inc., Anthos Therapeutics, Inc., ARCA biopharma, Inc., AstraZeneca Pharma India, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd, AstraZeneca, Produtos Farmaceuticos, Lda, Atentiv, LLC, Bayer, Bayer (Proprietary) Limited, Bayer Aktiengesellschaft, Bayer Pharma AG, Beth Israel Deaconess Medical Center, Better Therapeutics, Boston Clinical Research Institute, LLC, Bristol-Myers Squibb, CellResearch Corporation Pte Ltd, Cleerly, Inc., Colorado Dept of Public Health and Environment, Cook Regentec LLC, CSL Behring LLC, Eidos Therapeutics, Inc., EPG Communication Holdings Ltd., Esperion Therapeutics, Inc, Faraday Pharmaceuticals, Inc., HeartFlow Inc, Insmed, Ionis Pharmaceuticals, IQVIA Inc., Janssen Pharmaceuticals, Inc, Janssen Research & Development, LLC, Janssen Scientific Affairs LLC, Lexicon Pharmaceuticals, Inc., LSG Corporation, MedImmune Limited, Medpace, Inc., Medscape, Merck Sharp & Dohme Corp., Nectero Medical Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk, Osiris Therapeutics, Inc., Pfizer, PPD Development, L.P., Prothena Biosciences Limited, Regeneron, Regents of the University of Colorado (aka UCD), Sanifit Therapeutics S.A., Sanofi, Silence Therapeutics PLC, Stanford University, Stealth BioTherapeutics Inc., The Brigham & Women's Hospital, Inc., Thrombosis Research Institute, University of Colorado Denver, University of Pittsburgh, VarmX, WraSer, LLC. Dr. Bonaca receives support from the AHA SFRN under award numbers 18SFRN3390085 (BWH-DH SFRN Center) and 18SFRN33960262 (BWH-DH Clinical Project). Dr. Bonaca also reports stock in Medtronic and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}